• Explore /
  • Poster
  • / REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.

REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.

Abstract Poster

Authors

null

Daniel H. Ahn

Mayo Clinic Arizona, Phoenix, AZ

Daniel H. Ahn , Fang-Shu Ou , Bassam Bassam Sonbol , Donald Wender , Kelsey Klute , Zhaohui Jin , Jeremy Clifton Jones , Angela Ulrich , Blake Waechter , Heather Young , Benjamin Adam Weinberg , Heinz-Josef Lenz , John H. Strickler , Tanios S. Bekaii-Saab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

04117945

DOI

10.1200/JCO.2022.40.4_suppl.TPS213

Abstract #

TPS213

Poster Bd #

N5

Abstract Disclosures

Similar Posters

First Author: Yasushi Tsuji

First Author: Yasutoshi Kuboki

First Author: Nicolas Huyghe

First Author: Mehmet Akce